Genevant Sciences, Inc. is a Massachusetts-based biotechnology company that develops and delivers nucleic acid therapies. According to filings, it has paid about $100,000 to lobby on health and healthcare issues, working with the Prism Group on matters related to healthcare policy. The filings focus broadly on healthcare topics rather than specific bills or regulations.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
JAY BRETT PERRON
The latest disclosures for this client.
NOVEL STRATEGIES (FKA) PRISM GROUP
2TNOVEL STRATEGIES (FKA) PRISM GROUP
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
NOVEL STRATEGIES (FKA) PRISM GROUP